BioMarin to Use Myriad's HRD Test as CDx for Drug Candidate | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics today announced a research collaboration for use of the company's homologous recombination deficiency test to identify tumor types that may serve as targets for BioMarin's investigational drug candidate BMN-673.

Myriad's test detects tumors that may be susceptible to DNA-damaging drugs because they no longer can repair double-stranded DNA breaks.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.